Phosphoproteomic Analysis of Neoadjuvant Breast Cancer Suggests That Increased Sensitivity to Paclitaxel Is Driven by CDK4 and Filamin A

Researchers conducted a phosphoproteomic screening of samples from HER2-negative female breast cancer receiving neoadjuvant paclitaxel, aiming to find candidate biomarkers of paclitaxel sensitivity.